These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 35503478)

  • 1. Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets.
    Costa MD; Maciel P
    Cell Mol Life Sci; 2022 May; 79(5):274. PubMed ID: 35503478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
    Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
    Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA toxicity is a component of ataxin-3 degeneration in Drosophila.
    Li LB; Yu Z; Teng X; Bonini NM
    Nature; 2008 Jun; 453(7198):1107-11. PubMed ID: 18449188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
    Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
    J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.
    Mallik M; Lakhotia SC
    J Genet; 2010 Dec; 89(4):497-526. PubMed ID: 21273704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggregation of polyQ-extended proteins is promoted by interaction with their natural coiled-coil partners.
    Petrakis S; Schaefer MH; Wanker EE; Andrade-Navarro MA
    Bioessays; 2013 Jun; 35(6):503-7. PubMed ID: 23483542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms.
    van Ham TJ; Breitling R; Swertz MA; Nollen EA
    EMBO Mol Med; 2009 Nov; 1(8-9):360-70. PubMed ID: 20049741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genes and pathways affected by CAG-repeat RNA-based toxicity in Drosophila.
    Shieh SY; Bonini NM
    Hum Mol Genet; 2011 Dec; 20(24):4810-21. PubMed ID: 21933837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining genetic factors that modulate intergenerational CAG repeat instability in Drosophila melanogaster.
    Jung J; van Jaarsveld MT; Shieh SY; Xu K; Bonini NM
    Genetics; 2011 Jan; 187(1):61-71. PubMed ID: 21041558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring polyglutamine toxicity in yeast.
    Duennwald ML
    Methods; 2011 Mar; 53(3):232-7. PubMed ID: 21144902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi for the large non-coding hsromega transcripts suppresses polyglutamine pathogenesis in Drosophila models.
    Mallik M; Lakhotia SC
    RNA Biol; 2009; 6(4):464-78. PubMed ID: 19667761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AQAMAN, a bisamidine-based inhibitor of toxic protein inclusions in neurons, ameliorates cytotoxicity in polyglutamine disease models.
    Hong H; Koon AC; Chen ZS; Wei Y; An Y; Li W; Lau MHY; Lau KF; Ngo JCK; Wong CH; Au-Yeung HY; Zimmerman SC; Chan HYE
    J Biol Chem; 2019 Feb; 294(8):2757-2770. PubMed ID: 30593503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyglutamine tracts as modulators of transcriptional activation from yeast to mammals.
    Atanesyan L; Günther V; Dichtl B; Georgiev O; Schaffner W
    Biol Chem; 2012 Jan; 393(1-2):63-70. PubMed ID: 22628299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-scale screen for modifiers of ataxin-3-derived polyglutamine-induced toxicity in Drosophila.
    VoSSfeldt H; Butzlaff M; PrüSSing K; Ní Chárthaigh RA; Karsten P; Lankes A; Hamm S; Simons M; Adryan B; Schulz JB; Voigt A
    PLoS One; 2012; 7(11):e47452. PubMed ID: 23139745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila.
    Marsh JL; Walker H; Theisen H; Zhu YZ; Fielder T; Purcell J; Thompson LM
    Hum Mol Genet; 2000 Jan; 9(1):13-25. PubMed ID: 10587574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RACK1 modulates polyglutamine-induced neurodegeneration by promoting ERK degradation in Drosophila.
    Xie J; Han Y; Wang T
    PLoS Genet; 2021 May; 17(5):e1009558. PubMed ID: 33983927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel hydroxylamine derivative NG-094 suppresses polyglutamine protein toxicity in Caenorhabditis elegans.
    Haldimann P; Muriset M; Vígh L; Goloubinoff P
    J Biol Chem; 2011 May; 286(21):18784-94. PubMed ID: 21471208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of common genetic modifiers of neurodegenerative diseases from an integrative analysis of diverse genetic screens in model organisms.
    Chen X; Burgoyne RD
    BMC Genomics; 2012 Feb; 13():71. PubMed ID: 22333271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Genetic Variation in Yeast Reveals That NEDD4 Is a Conserved Modifier of Mutant Polyglutamine Aggregation.
    Peters TW; Nelson CS; Gerencser AA; Dumas KJ; Tavshanjian B; Chang KC; Lithgow GJ; Hughes RE
    G3 (Bethesda); 2018 Nov; 8(11):3421-3431. PubMed ID: 30194090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genomewide RNA interference screen for modifiers of aggregates formation by mutant Huntingtin in Drosophila.
    Zhang S; Binari R; Zhou R; Perrimon N
    Genetics; 2010 Apr; 184(4):1165-79. PubMed ID: 20100940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.